• 2005

Company Description

ZIOPHARM Oncology is an American biopharmaceutical company developing novel therapeutics for the treatment of cancer.

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System to turn on and off and precisely modulate gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. Multiple new INDs for new targets using similar technology are expected in 2014 and 2015. ZIOPHARM is also developing novel small molecules as potential cancer therapeutics.

  • Manufacturer:

    Science and Engineering
  • Formed:

    2005
  • Company Website:

  • Company E-mail:

  • Company Address:

    1180 Avenue of the Americas
    New York, NY
    United States
  • CEO:

    • Laurence Cooper